Amgen, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Amgen, Inc. trades at $415.64 (market cap $224.14B), while Vanguard Short Term Corporate Bond ETF trades at $78.6. The key difference: Amgen, Inc. pays a 2.43% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | VCSH | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Fixed Income |
52-Week High | $417.20 | $80.20 |
52-Week Low | $271.18 | $78.41 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
VCSH trades at $78.615, up 0.16% with a bearish technical outlook as moving averages signal selling pressure while oscillators remain neutral. The ETF maintains a 4.77% yield with short 2.7-year duration, though recent analysis suggests limited upside due to tight credit spreads. Recent institutional activity shows mixed positioning with Apella Capital reducing holdings while Bessemer Group and Allspring increased stakes significantly.
The outlook remains cautious with downgrades to 'Hold' citing unattractive entry points, though the short duration provides downside protection. Key risks include credit spread widening and Fed policy uncertainty, while the primary opportunity lies in stable income generation for conservative investors seeking corporate bond exposure.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →